Epitope characterization of MUC1 antibodies

被引:20
|
作者
Blockzjil, A [1 ]
Nilsson, K [1 ]
Nilsson, O [1 ]
机构
[1] CanAg Diagnost AB, SE-41455 Gothenburg, Sweden
关键词
MUC1; epitope specificity; CA; 15-3; pepscan analysis; TD-4;
D O I
10.1159/000056504
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The specificities of the 56 MAbs submitted to the ISOBM TD-4 Workshop were characterized by ELISA assays against MUC1-positive (ZR75-1) and MUC1-negative cell lines (LS174T), binding to a 20-mer peptide corresponding to the tandem repeat region of MUC1! apoprotein, and Pepscan analysis of overlapping 9-mer peptides corresponding to the tandem repeat region of MUC1., The recognition of soluble MUC1 antigen from ZR75-1 cell line was also tested in two-site EIA using the ISOBM TD-4 MAb as catching MAb, The studies indicated that 35 of the submitted antibodies recognized epitopes expressed in the MUC1 tandem repeat region, and that 30 of these recognized epitopes within the immunodominant region (PDTRPAP) of the tandem repeat, Recognition of soluble MUC1 from ZR75-1 cell line indicated that additional 10 MAb recognized epitopes 'outside' the tandem repeat region of MUC1 from ZR75-1 cell line, or that the antibodies recognized epitopes depending on the glycosylation of the MUC1 tandem repeat. Six MAbs reacted only with the MUC1-negative cell line LS 174T, and thus most likely did not recognize epitopes specific for MUC1.
引用
收藏
页码:46 / 56
页数:11
相关论文
共 50 条
  • [11] Mouse mucin 1 (MUC1) defined by monoclonal antibodies
    Xing, PX
    Lees, C
    Lodding, J
    Prenzoska, J
    Poulos, G
    Sandrin, M
    Gendler, S
    McKenzie, IFC
    INTERNATIONAL JOURNAL OF CANCER, 1998, 76 (06) : 875 - 883
  • [12] Characterization of a panel of monoclonal antibodies using GalNAc glycosylated peptides and recombinant MUC1
    Reis, CA
    Hassan, H
    Bennett, EP
    Clausen, H
    TUMOR BIOLOGY, 1998, 19 : 127 - 133
  • [13] Reactivity of natural and induced human antibodies to MUC1 mucin with MUC1 peptides and N-acetylgalactosamine (GalNAc) peptides
    von Mensdorff-Pouilly, S
    Petrakou, E
    Kenemans, P
    van Uffelen, K
    Verstraeten, AA
    Snijdewint, FGM
    van Kamp, GJ
    Schol, DJ
    Reis, CA
    Price, MR
    Livingston, PO
    Hilgers, J
    INTERNATIONAL JOURNAL OF CANCER, 2000, 86 (05) : 702 - 712
  • [14] Determination of carbohydrate specificity of monoclonal antibodies against MUC1
    Galanina, OE
    Simeoni, LA
    Ter-Grigoryan, AG
    Belyanchikov, IM
    Bovin, NV
    TUMOR BIOLOGY, 1998, 19 : 79 - 87
  • [15] Screening of anti-MUC1 antibodies for reactivity with native (ascites) and recombinant (baculovirus) MUC1 and for blocking MUC1 specific cytotoxic T-lymphocytes
    Ciborowski, P
    Konitzki, WM
    Blander, JM
    Finn, OJ
    TUMOR BIOLOGY, 1998, 19 : 147 - 151
  • [16] MUC1 and cancer
    Taylor-Papadimitriou, J
    Burchell, J
    Miles, DW
    Dalziel, M
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 1999, 1455 (2-3): : 301 - 313
  • [17] Expression, purification and characterization of the MUC1 tandem repeat
    Brokx, RD
    Yang, SX
    Gariepy, J
    MOLECULAR BIOLOGY OF THE CELL, 2001, 12 : 67A - 67A
  • [18] Running a MUC1
    Nicola McCarthy
    Nature Reviews Cancer, 2012, 12 : 317 - 317
  • [19] MUC1 immunotherapy
    Beatson, Richard E.
    Taylor-Papadimitriou, Joyce
    Burchell, Joy M.
    IMMUNOTHERAPY, 2010, 2 (03) : 305 - 327
  • [20] RUNNING A MUC1
    McCarthy, Nicola
    NATURE REVIEWS CANCER, 2012, 12 (05) : 317 - 317